We are pleased to announce our participation as a platinum sponsor at next week's International Society for Cellular Therapy (ISCT) 22nd Annual Meeting in Singapore. This will be the first time that the ISCT Annual Meeting will be held in Asia and is a reflection of the increasing global awareness of the importance of Asia in the field of Cellular Therapies. With over 1000 international delegates registered to attend, ISCT 2016 is a great opportunity to network with experts within the global cell therapy arena. We are honored to showcase our global integrated solution for cell therapy clinical and commercial development in conjunction with our parent company, Thermo Fisher Scientific.
From booth E01, we will showcase our comprehensive cell therapy offering, highlighting products and services which support the entirety of the workflow. We are also hosting several insightful sessions:
ISCT Flow Cytometry Workshop
Date: Wednesday, May 25th
Time: 12:50–13:50 PM
Title: Flow cytometry in manufacturing of cell-based products for cellular therapy
Presented by Edouard Bernet, MSc, Thermo Fisher Scientific - SIN
The 2016 Flow Cytometry Workshop will follow-up on last year's focus on standardization for translational and clinical applications with the theme "flow cytometry in manufacturing of cell-based products for cellular therapy." The program contains plenary sessions on variability and robustness, QA/QC, product characterization by flow cytometry, and sustainable flow cytometry. The speaker will discuss QC quality check for in-process and end point identity check.
Registration: Please note that registration for the Flow Cytometry Workshop is not included with the main meeting registration. Register here.
Date: Thursday, May 26th
Time: 12:30 PM
Location: Room 331
Title: The red pill or the blue pill; how to make choices that will support early translation and commercial success
Presented by Jef Pinxteren, PhD, Head of Research & Development, ReGenesys BVBA
This lecture will address considerations for translating regenerative medicine technologies into the clinic. Material selection, quality, manufacturing technologies, and characterization play important roles as choices are made during the development phase of a cell therapy product. These early choices can have a significant impact on successful scale-up and commercialization. This workshop will present examples of important points to consider when progressing therapies down the development path. Discussion topics will include the importance of material selection, methods for characterization, manufacturing technology evaluation, methods to consider for scale-up, the risks associated with the use of serum, and data supporting the use of serum replacements.
- Selective Ex Vivo T cell Expansion Using Next Generation Expansion Dynabeads™ Technology, Hilde Almåsbak et al.
- Optimized Dynabeads Treg CD3/CD28 for Regulatory T cell Activation and Expansion, Kerstin Bernstrom et al.
- Serum Free Clinical Grade Large Scale Lentiviral Production System for Gene Therapy Application, Xin Yu, Mu Li, and Xavier de Mollerat du Jeu.
We look forward to sharing our solutions with you and discussing the latest breakthroughs in cell therapy research. To learn more about our cell therapy solutions, we encourage to read our blog or download our eBook Commercially Successful Cell Therapies: Navigating the Ultra Cold Chain Distribution Minefield.